FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1) By Ogkologos - April 11, 2025 1352 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-811 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Virtual Mind–Body Fitness Classes Show Unexpected Benefit in People with Cancer December 15, 2023 Reflecting On My Time As the Cancer.Net Editor in Chief May 26, 2021 Daratumumab Plus Bortezomib and Dexamethasone Regimen Significantly Prolongs OS in Patients... November 30, 2022 Efficacy and Safety of Datopotamab Deruxtecan in Patients with Pretreated Advanced/Metastatic... January 27, 2025 Load more HOT NEWS Nurse Diagnosed with Stage IV Cancer After Thinking Her Pain Was... Four randomized prospective degree compared 90 days regarding neoadjuvant ADT observed... FDA Grants Accelerated Approval to Ponatinib with Chemotherapy for Newly Diagnosed... ESMO Immuno-Oncology Congress 2024, Geneva, Switzerland, 11-13 December
